ClinicaliQ Trial Snapshot
- Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma — Recruiting • Phase II • Oncology • NCT05702229.
- What is being tested: Novel combination therapies (multi-drug regimens) evaluated for efficacy, safety, tolerability, pharmacokinetics, and immunogenicity in gastric and gastroesophageal junction adenocarcinoma.
- Patient eligibility overview: Participants with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, representing patients with advanced disease unsuitable for surgical resection.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
Eligibility Snapshot
- : * 18 years or older at the time of signing the ICF. * Body weight > 35 kg. * Previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. * Has measurable target disease assessed by the Investigator based on RECIST 1.1. * ECOG PS zero or one. * Life expectancy of at least 12 weeks. * Adequate organ and bone marrow function. * Has central lab confirmed Claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh biopsy when Substudy 3, Substudy 4 i s open for recruitment.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.